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Abstract 
Two heteroleptic bis(2,2':6',2''-terpyridine)chromium(III) complexes [Cr(1)(4'-(4-
tolyl)tpy)][CF3SO3]3 and [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 in which 1 and 2 contain 4'-(4-
(N,N-diphenylamino)phenyl) or 4'-(4-(N,N-di(4-methoxyphenyl)amino)phenyl) domains, 
respectively, have been prepared and their spectroscopic and electrochemical properties 
compared with those of [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3 and [Cr(1)2][CF3SO3]3. The single 
crystal structure of [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3.2MeCN is presented, and the effects of 
accommodating three triflate anions and two MeCN molecules per cation are discussed in 
terms of related structures. The coordination of 1 or 2 to chromium(III) red-shifts the ILCT 
band and this band exhibits a negative solvatochromic effect in some solvents. However, in 
H2O, MeOH, DMSO and DMF, the tpy ligands are labile; spectroscopic data for a study of 
[Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 are consistent with the formation of [Cr(4'-
Xtpy)(Solv)3]3+ (Solv = solvent) rather than complete ligand displacement or a ligand 
redistribution.  
Keywords:  Chromium(III); 2,2':6',2''-terpyridine; solvatochromic; absorption spectra; 
heteroleptic complex 
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1. Introduction 
Although large numbers of metal complexes containing 2,2':6',2''-terpyridine (tpy) metal-
binding domains have been reported in the past 80 years, those with chromium(III) remain 
underexplored since the homoleptic [Cr(tpy)2]n (n = +3, +2, +1, 0, –1) complexes were 
described in the 1960s [1,2,3,4,5,6]. In 2012, Sproules, Wieghardt and coworkers proposed 
that in the series [Cr(tpy)2][PF6]n with n = 3, 2 1, 0, all one-electron redox processes are 
ligand-based with the chromium centre remaining in the +3 oxidation state [7]. This and 
other photophysical and electrochemical investigations of complexes having {Cr(tpy)2}3+ 
cores have dealt with homoleptic complexes [8,9,10,11,12,13,14,15,16]. The complexes 
excited some interest as potential catalysts for photoelectrochemical water-splitting with 
the observation that in the solid state water molecules were located close to the metal 
centre in pockets created by the two orthogonal tpy ligands [17,18]. We recently showed 
that heteroleptic [Cr(4'-Xtpy)(4'-Ytpy)]3+ complexes can be conveniently accessed using 
the general method shown in Scheme 1, and demonstrated that these complexes do not 
behave as typical kinetically inert d3 species [19]. We now describe the preparation and 
properties of chromium(III) complexes incorporating ligands 1 and 2 (Scheme 2). The 
extended π-systems and peripheral diphenylamine domains in 1 and 2 provide a facile 
means of tuning the photophysical properties of the {Cr(tpy)2}3+ complex. 
 
 
Scheme 1. General route to heteroleptic [Cr(4'-Xtpy)(4'-Ytpy)][CF3SO3]3 complexes. 
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Scheme 2. Structures of ligands. 
 
2. Experimental 
2.1  General  
1H and 13C NMR spectra were recorded on a Bruker Avance III-500 spectrometer with 
chemical shifts referenced to residual solvent peaks	(∂(TMS) = 0 ppm). Absorption 
spectra were recorded on a Cary 5000 spectrophotometer on an Agilent Technologies 
UV-Visble 8453 spectrophotometer. Electrochemical measurements were made on a CH 
Instruments 900B potentiostat using glassy carbon, platinum wire and a silver wire as the 
working, counter, and pseudo reference electrodes, respectively. Samples were dissolved in 
HPLC grade MeCN (10–4 to 10–5 mol dm–3) containing 0.1 mol dm–3 [nBu4N][PF6] as 
supporting electrolyte; all solutions were degassed with argon. Cp2Fe was used as internal 
reference added at the end of experiments. 
 The compounds 4'-(4-tolyl)-tpy [20], 1 [21] and 2 [21] were prepared as reported. 
 
2.2  [Cr(1)Cl3] 
Anhydrous CrCl3 (188 mg, 1.18 mmol) and 1 (731 mg, 1.53 mmol) were suspended in 
EtOH (15 mL). Granulated zinc (16.9 mg, 0.259 mmol) was added, and then the reaction 
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mixture was heated at reflux for 6 h, after which it was filtered, leaving excess zinc in the 
reaction flask. The precipitated [Cr(1)Cl3] was collected on the filter-frit, washed with 
EtOH and used in the next step without further purification. IR: (solid, ν /cm–1) 501 (s), 
519 (m), 612 (w), 650 (w), 661 (s), 690 (s), 695 (s), 719 (w), 728 (s), 751 (s), 790 (s), 827 
(w), 834 (s), 890 (m), 899 (w), 1017 (w), 1026 (s), 1034 (w), 1066 (w), 1078 (w), 1099 
(w), 1186 (w), 1205 (m), 1244 (s), 1262 (w), 1271 (w), 1289 (w), 1338 (m), 1367 (w), 
1411 (m), 1436 (w), 1446 (w), 1467 (m), 1489 (m), 1520 (m), 1547 (w), 1568 (m), 1576 
(s), 1582 (s), 1603 (m), 3059 (w), 3061 (w), 3998 (w). Found C 62.57, H 4.07, N 9.07;  
C33H24Cl3CrN4 requires C 62.43, H 3.81, N 8.82. 
 
2.3  [Cr(1)(O3SCF3)3] 
[Cr(1)Cl3] (75.0 mg, 0.118 mmol) was dissolved in CF3SO3H (0.4 mL, 4.4 mmol) and the 
dark red solution was stirred overnight at room temperature. The mixture was then cooled 
to 0 oC and Et2O (20 mL) was added, yielding a dark red precipitate. The solid was 
separated by filtration, washed with Et2O and dried in air. [Cr(1)(O3SCF3)3] was isolated as 
a dark red solid (72.8 mg, 0.0746 mmol, 67.8 %). Found C 43.96, H 2.71, N 6.03; 
C36H24CrF9N4O9S3 requires C 44.31, H 2.48, N 5.74.   
 
2.4  [Cr(1)2][CF3SO3]3 
A mixture of [Cr(1)(CF3SO3)3] (50.0 mg, 51.2 µmol) and 1 (26.9 mg, 56.4 µmol) in MeCN 
(2 mL) was heated at reflux for 7 h. The crude product was recrystallized from EtOH and 
[Cr(1)2][CF3SO3]3 was isolated as a dark red solid (18.2 mg, 12.5 µmol, 24.4 %). IR: 
(solid, ν/cm–1) 503 (s), 570 (m), 635 (s), 661 (m), 691 (m), 717 (m), 749 (m), 786 (m), 829 
(m), 1026 (s), 1068 (m), 1094 (m), 1120 (m), 1142 (s), 1198 (s), 1222 (s), 1240 (s), 1332 
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(m), 1366 (m), 1418 (m), 1439 (m), 1476 (s), 1520 (m), 1568 (s), 1575 (s), 1605 (m), 3075 
(w), 3497 (w). Found C 56.24, H 3.64, N 7.83; C69H48CrF9N8O9S3.H2O requires C 56.36, 
H 3.43, N 7.62. 
 
2.5  [Cr(4'-(4-tolyl)tpy)Cl3] 
The compound was prepared by the same procedure as [Cr(1)Cl3], starting with anhydrous 
CrCl3 (761 mg, 4.76 mmol) and 4'-(4-tolyl)tpy (2.00 g, 6.18 mmol) suspended in EtOH (60 
mL). Granulated zinc (68.2 mg, 1.05 mmol) was added and the mixture was heated at 
reflux for 4.25 h. [Cr(4'-(4-tolyl)tpy)Cl3] precipitated and was collected on a filter-frit, 
washed with EtOH and used in the next step without further purification. IR: (solid, ν/cm–
1) 501 (s), 519 (m), 612 (w), 650 (w), 661 (s), 690 (s), 695 (s), 719 (w), 728 (s), 751 (s), 
790 (s), 827 (w), 834 (s), 890 (m), 899 (w), 1017 (w), 1026 (s), 1034 (w), 1066 (w), 1078 
(w), 1099 (w), 1186 (w), 1205 (m), 1244 (s), 1262 (w), 1271 (w), 1289 (w), 1338 (m), 
1367 (w), 1411 (m), 1436 (w), 1446 (w), 1467 (m), 1489 (m), 1520 (m), 1547 (w), 1568 
(m), 1576 (s), 1582 (s), 1603 (m), 3059 (w), 3061 (w), 3998 (w). Found C 54.96, H 3.86, N 
8.58; C22H17Cl3CrN3 requires C 54.85, H 3.56, N 8.72. 
 
2.6 [Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3 
[Cr(4'-(4-tolyl)tpy)Cl3] (91.9 mg, 0.191 mmol) was dissolved in CF3SO3H (1.7 ml, 7.6 
mmol) and the dark red solution was stirred at room temperature overnight. The mixture 
was then cooled to 0 oC and Et2O (20 mL) was added to precipitate [Cr(4'-(4-
tolyl)tpy)(O3SCF3)3]. The product was separated by filtration, washed with Et2O and dried 
under a flow of N2, before being dissolved in MeCN (10 mL). This solution was added to  
a flask containing 1 (100 mg, 0.210 mmol). The reaction mixture was heated at reflux for 
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5.5 h, after which time solvent was removed. The product was purified by recrystallization 
from EtOH and was washed with Et2O. [Cr(1)(4'-(4-tolyl)tpy)][O3SCF3]3 was isolated as a 
dark red solid (236 mg, 0.182 mmol, 95.2 %). IR: (solid, ν/cm–1) 573 (m), 635 (s), 662 
(m), 693 (m), 725 (w), 755 (m), 786 (m), 823 (w), 846 (w), 885 (w), 1026 (s), 1068 (w), 
1096 (m), 1147 (s), 1198 (m), 1222 (s), 1244 (s), 1336 (w), 1367 (w), 1423 (m), 1464 (m), 
1475 (m), 1478 (m), 1520 (w), 1538 (m), 1564 (m), 1569 (m), 1579 (m), 1602 (m), 3071 
(w), 3498 (w). Found C 51.99, H 3.36, N 7.42; C58H41CrF9N7O9S3.2H2O requires C 52.17, 
H 3.40, N 7.34.  
 
2.7 [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 
The method was as for [Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3, starting with [Cr(4'-(4-
tolyl)tpy)Cl3] (34.8 mg, 72.2 µmol) and CF3SO3H (0.5 ml, 5.6 mmol) in the first 
step, and then 2 (42.6 mg, 79.4 µmol) and a reaction time of 6 h in the second step. 
[Cr(2)(4'-(4-tolyl)tpy)][O3SCF3]3 was isolated as a dark red solid (85.7 mg, 63.1 µmol, 
43.7%). Found C 52.77, H 3.85, N 6.99; C60H45CrF9N7O11S3 requires C 53.02, H 3.34, N 
7.21.  
 
2.8  [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3 
The method was as for [Cr(1)(4'-(4-tolyl)tpy)][O3SCF3]3, starting with [Cr(4'-(4-
tolyl)tpy)Cl3] (164 mg, 0.341 mmol) and CF3SO3H (1.2 mL, 14 mmol) in the first 
step, and then 4'-(4-tolyl)tpy (121 mg, 0.375 mmol) and a reaction time of 6.5 h in the 
second step. The product precipitated during the reaction and was separated by filtration 
and recrystallized from hot MeCN. [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3 was isolated as an 
orange solid (302 mg, 0.263 mmol, 77.0%). IR: (solid, n/cm–1) 500 (s), 505 (s), 517 (s), 
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529 (m), 572 (m), 613 (m), 625 (s), 634 (s), 662(w), 693 (w), 727 (w), 778 (m), 788 (m), 
823 (m), 949 (w), 996 (m), 1027 (s), 1097 (w), 1116 (m), 1138 (m), 1158 (s), 1210 (m), 
1222 (m), 1249 (s), 1363 (w), 1406 (w), 1435 (w), 1478 (w), 1533 (w), 1539 (w), 1601 (s), 
1618 (w), 3066 (w). Found C 49.34, H 3.40, N 8.70; C47H34CrF9N6O9S3.MeCN requires C 
49.58, H 3.14, N 8.26.  
 
2.9 Crystallography 
Single crystal data were collected on a Bruker APEX-II diffractometer with data reduction, 
solution and refinement using the programs APEX [22] and SHELX-13 [23]. The 
structural diagrams and structure analysis were carried out using Mercury v. 3.0.1 or 3.3 
[24,25]. 
 [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3.2MeCN: C51H40CrF9N8O9S3, M = 1228.12, yellow 
needle, monoclinic, space group C2/c, a = 14.5535(8), b = 17.1633(11), c = 21.9247(14) 
Å, β = 108.308(4)o, U = 5199.3(6) Å3, Z = 4, Dc = 1.569 Mg m–3, µ(Cu-Kα) =  3.802 
mm−1, T = 123 K. Total 17034 reflections, 4644 unique, Rint = 0.0512. Refinement of 3700 
reflections (404 parameters) with I >2σ(I) converged at final R1 = 0.0383 (R1 all data = 
0.0539), wR2 =  0.0906 (wR2 all data = 0.0984), gof = 1.019. 
3 Results and discussion 
3.1 Synthesis of the chromium(III) complexes 
The ligands 4'-(4-tolyl)tpy, 1 and 2 were prepared as previously reported [20,21]. The 
synthesis of related pairs of homoleptic and heteroleptic coplexes containing a {Cr(tpy)2}3+ 
core was achieved using the general method shown in Scheme 1. [Cr(4'-(4-tolyl)tpy)Cl3] 
and [Cr(1)Cl3] were prepared by treating CrCl3 with the appropriate ligand in the presence 
of zinc in ethanol [19], and subsequent reaction with triflic acid gave [Cr(4'-(4-
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tolyl)tpy)(O3SCF3)3] and [Cr(1)(O3SCF3)3], respectively. Although these complexes may 
be isolated, it is more convenient to prepare them as required and use them in situ for 
reaction with a second equivalent of tpy ligand. Scheme 3 summarizes the formation of 
[Cr(4'-(4-tolyl)tpy)2][CF3SO3]3, [Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3 and [Cr(2)(4'-(4-
tolyl)tpy)][CF3SO3]3. The homoleptic complex [Cr(1)2][O3SCF3]3 was prepared in an 
analogous manner by treatment of [Cr(1)(O3SCF3)3] with ligand 1. Elemental analyses for 
the homoleptic and heteroleptic triflate salts were satisfactory. Attempts to record their 
MALDI-TOF or electrospray mass spectra did not yield interpretable data, a problem 
encountered with other bis(tpy) chromium(III) complexes [19].  
 
Scheme 3. Synthetic routes to [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3, [Cr(1)(4'-(4-
tolyl)tpy)][CF3SO3]3 and [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3. 
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3.2 Crystal structure of [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3.2MeCN 
Structural data for complexes containing {Cr(tpy)2} domains are surprisingly few. The 
Cambridge Structural Database [26] (searched using Conquest v. 1.16 [24], CSD v. 5.35 
with updates up to May 2014) contains only seven examples, four of which contain 
chromium(III) [17,18,19]. The structure of the [Cr(4'-(4-tolyl)tpy)2]3+ cation (Figure 1) was 
confirmed by a single crystal determination of [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3.2MeCN. 
The crystals were grown serendipitously from a MeOH solution of the crude product of a 
trial reaction of [Cr(4'-(4-tolyl)tpy)(CF3SO3)3] with 5,5''-dimethyl-2,2':6',2''-terpyridine 
(5,5''-Me2tpy) in MeCN under microwave conditions (150 oC, 11 bar); crystals grew after 
slow evaporation of solvent over a period of several weeks. The isolation of the homoleptic 
complex rather than the target [Cr(4'-(4-tolyl)tpy)(5,5''-Me2tpy)][CF3SO3]3 can be 
understood in terms of lability of the ligands in [Cr(tpy)2]3+ complexes [19]. [Cr(4'-(4-
tolyl)tpy)2][CF3SO3]3.2MeCN crystallizes in the monoclinic space group C2/c, and the 
asymmetric unit contains half of the cation, the other half being generated by rotation 
about a 2-fold axis. The asymmetric unit also contains one ordered [CF3SO3]– ion, one 
half-occupancy, disordered anion which lies on a 2-fold axis, and one ordered MeCN 
molecule. The bond distances and angles in the coordination sphere of atom Cr1 (caption 
to Figure 1) are comparable with those in [Cr(tpy)(4'-(4-tolyl)tpy)][PF6]3.3MeCN [19]. The 
phenyl ring is twisted through 18.5o with respect to the plane of the pyridine ring 
containing C8, and this compares to 24.4o in [Cr(tpy)(4'-(4-tolyl)tpy)]3+ [19], and with 
29.2o and 16.0o or 28.7o and 27.8o for the two independent molecules in each of the two 
polymorphs of the free 4'-(4-tolyl)tpy ligand [27,28]. 
 10 
 
Fig. 1.  Structure of the [Cr(4'-(4-tolyl)tpy)2]3+ cation in [Cr(4'-(4-
tolyl)tpy)2][CF3SO3]3.2MeCN (ellipsoids plotted at 50% probability level and H atoms 
omitted for clarity). Important bond distances and angles: Cr1–N1 = 2.061(2), Cr1–N2 = 
1.9717(18), Cr1–N3 = 2.055(2) Å; N2–Cr1–N1 = 78.79(8), N2–Cr1–N3 = 78.59(8), N2–
Cr1–N2i = 177.92(11)o (symmetry code i = 1–x, y, 1/2–z). 
 
 
 The packing of cations in [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3.2MeCN involves multiple 
embraces [29]. Figure 2a depicts the principal packing motif, comprising a head-to-tail π-
stacking interaction between centrosymmetric pairs of cations. The pyridine ring 
containing N3 stacks over the arene ring of the tolyl substituent containing atom C19ii 
(symmetry code ii = 1–x, –y, 1–z). The inter-centroid distance is 3.71 Å, and the angle 
between the ring planes is 17.4o. Propagaton of this motif results in the assembly of chains 
that follow the crystallographic c-axis (Figure 2b), although there are no close π-contacts 
between chains. This is seen in Figure 2c which views four adjacent chains, the cavities 
between which are occupied by the triflate anions and MeCN molecules. 
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(a) 
  
(b)         (c) 
Figure 2. (a) Centrosymmetric head-to-tail embrace of [Cr(4'-(4-tolyl)tpy)2]3+ cations. 
Assembly of chains along the c-axis; adjacent molecules are coloured red and blue. (c) 
Four adjacent chains viewed down the c-axis. (Colour online) 
 
 
 The interactions between cations in [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3.2MeCN  
contrasts dramatically with the motifs observed in [Fe(4'-(4-tolyl)tpy)2][PF6]2.2.2MeCN 
and [Ru(4'-(4-tolyl)tpy)2][PF6]2.1.75MeCN in which the cations pack into rows with face-
to-face π-interactions between pairs of outer pyridine rings [28]. In order to ascertain 
whether this change in structural paradigm is associated with the change in oxidation state 
of the metal, we have considered other structurally determined [M(4'-(4-tolyl)tpy)2]3+ 
complexes.  
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 The space group and cell dimensions for [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3.2MeCN 
(C2/c, a = 14.5535(8), b = 17.1633(11), c = 21.9247(14) Å, β = 108.308(4)o) are very 
similar to those for [Mn(4'-(4-tolyl)tpy)2][PF6]3.2MeCN (CSD refcode QOQJOW, C2/c, a 
= 14.788(2), b = 16.140(2), c = 21.467(3) Å, β = 105.93(1)o [30] and [Ir(4'-(4-
tolyl)tpy)2][PF6]3.2MeCN (refcode YIDAU01, C2/c, a = 14.7995(5), b = 16.4658(5), c = 
21.5521(7) Å, β = 105.5450(8)o [31], and YIDAU02, C2/c, a = 14.6977(14), b = 
16.3737(16), c = 21.420(2) Å, β = 105.639(2)o [32]). An additional determination for 
[Ir(4'-(4-tolyl)tpy)2][PF6]3.2MeCN (refcode YIDAU) reports that the complex crystallizes 
in the Cc space group with a = 14.7995(5), b = 16.4658(5), c = 21.5521(7) Å, β = 
105.5450(8)o [33]. Each of these metal(III) complexes assembles with the same π-stacked 
motif shown in Figure 2a, although the change from triflate to hexafluoridophosphate 
anions causes a shift in the chains from following the c-axis to running obiquely through 
the ac-plane. The common assembly motif seen in these metal(III) salts is not present in 
any of the salts of [M(4'-(4-tolyl)tpy)2]2+ complexes deposited in the CSD (refcodes 
DIKYIG [30,34], KAYHIC [35], KEMWEG [36], KUWKOD [37] and QOLYUM [38]). 
These observations suggest that the accommodation of three anions ([PF6]– or [CF3SO3]–) 
and two MeCN molecules per [M(4'-(4-tolyl)tpy)2]3+ (M = Mn, Cr or Ir) leads to a 
common packing motif.  
 
3.3 Absorption spectroscopic properties 
Compared to tpy or 4'-(4-tolyl)tpy, the introduction of 4'-(4-(N,N-diphenylamino)phenyl) 
or 4'-(4-(N,N-di(4-methoxyphenyl)amino)phenyl) substituents results in the solution 
electronic absorption spectra of the free ligands extending into the visible region [21]. The 
ligands exhibit a characteristic intra-ligand charge transfer (ILCT) band with the tertiary 
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amine acting as an electron donor [39]. This charge separation is stabilized by 
coordination, causing a red-shift in the ILCT band [39,40], as reported for complexes of 
ruthenium, osmium, iridium, zinc and cadmium containing 1 or 2 [21,41,42,43,44,45,46]. 
In MeCN solution, the ILCT maxima for [Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3 and [Cr(2)(4'-
(4-tolyl)tpy)][CF3SO3]3 are 507 nm (ε = 22 200 dm3 mol–1  cm–1) and 523 nm (ε = 21 100 
dm3 mol–1  cm–1), respectively, and the solutions are dark red. Figure 3 compares the 
absorption spectra of MeCN solutions of [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3, [Cr(1)(4'-(4-
tolyl)tpy)][CF3SO3]3 and [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3. Each of the heteroleptic 
complexes exhibits a broad, low intensity band (665 nm for [Cr(1)(4'-(4-
tolyl)tpy)][CF3SO3]3 and 708 nm for [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3). 
 
Figure 3. Absorption spectra of solutions of [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3 (black line), 
[Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3 (red line) and [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 (blue 
line) in MeCN (5 × 10–5  mol dm–3). 
 
The ILCT absorption band in the solution spectra of [Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3 and 
[Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 shifts to higher energies in solvents of increasing 
polarity, and we investgated this negative solvatochromism [47] in more detail for 
[Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3. Figure 4 illustrates the shift in λmax from 574 nm in 
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CHCl3 to 526 nm in MeCN, and the data correlate well with trends in solvent dipole 
moments and dielectric constants (Table 1).   
 
Table 1   Relationship between λmax for the ILCT band in [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 and dipole 
moment and dielectric constant of the solvent. 
Solvent λmax/ nm Dipole moment / D Dielectric constant 
CHCl3 574 1.15 4.81 
CH2Cl2 563 1.14 8.93 
EtOH 550 1.69 24.3 
Acetone 526 2.69 20.7 
MeCN 528 3.44 37.5 
 
Figure 4. Solution absorption spectra of [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 in different 
solvents (concentration = 5 × 10–5  mol dm–3), normalized with respect to the band ca. 500 
nm. (Colour on line.) 
 
 The absorption spectra of solutions of [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 in the 
solvents shown in Figure 4 did not change when monitored over a period of a week. 
However, in H2O, MeOH, DMSO and DMF, significant changes were observed, indicating 
that the complexes are not stable in these solvents. Figure 5a illustrates the absorption 
spectrum of a DMF solution of [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 monitored over 6 hours; 
no further change was observed after this period. The ILCT band initially with λmax = 520 
nm (ε = 11950 dm3 mol–1  cm–1) decays to a band with λmax = 483 nm (ε = 6600 dm3 mol–
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1  cm–1), and the weaker absorption (initially at 695 nm) evolves into a shoulder at 580 nm 
(Figure 5b). Several reaction pathways (Scheme 4) can be considered: (i) complete ligand 
displacement by DMF to give [Cr(DMF)6]3+, (ii) partial ligand displacement, or (iii) ligand 
redistribution to give a mixture of [Cr(2)(4'-(4-tolyl)tpy)]3+, [Cr(2)2]3+ and [Cr(4'-(4-
tolyl)tpy)2]3+. Absorptions >450 nm can only arise from chromium(III)-containing species. 
[Cr(DMF)6]3+ exhibits an absorption at 592 nm (assigned to the 4T2g ← 4A2g transition and 
with ε = 54 dm3 mol–1  cm–1) [48,49,50], but the ≈1000-fold difference in extinction 
coefficients allows us to eliminate [Cr(DMF)6]3+ as the origin of the absorption. The lowest 
energy absorption in the spectrum of a DMF solution of 2 appears at 367 nm (ε = 22700 
dm3 mol–1 cm–1). Hence, we assign the absorption at 483 nm to chromium(III)-bound 2, 
rather than free ligand (Figure 5c). The intense absorption at 344 nm in Figure 5a which 
loses intensity over time is characteristic of a {CrIII(4'-(4-tolyl)tpy)} chromophore (Figure 
3) [19]. These data, coupled with the increase in intensity of the high energy absorption at 
288 nm, are consistent with the lability of both 2 and 4'-(4-tolyl)tpy in DMF. Similar 
spectral changes are also seen over time for H2O, DMSO or MeOH solutions of [Cr(2)(4'-
(4-tolyl)tpy)][CF3SO3]3. In each case, the final spectrum is not consistent with complete 
ligand loss (Figure 5c), but rather suggests the presence of a mixture of the solvento 
complexes [Cr(2)(Solv)3]3+ and [Cr(4'-(4-tolyl)tpy)(Solv)3]3+ where Solv = solvent. The 
results are consistent with our previous observations that both ligands in [Cr(tpy)(4'-(4-
tolyl)tpy)][PF6]3 and [Cr(tpy)(5,5''-Me2tpy)][PF6]3 are labile in the presence of fluoride ion; 
in this case we were able to show that the absorption maximum of the final solution 
corresponded to that reported for [Cr(tpy)F3] [19,51]. 
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(a)  
(b)  
(c)  
 
Figure 5. (a) Solution absorption spectra of [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 in DMF 
(concentration = 5 × 10–5  mol dm–3) over a period of 6 hours, and (b) an expansion of the 
ILCT bands for the initial and final spectra. (c) Comparison of the DMF solution spectra of 
free ligands 2 and 4'-(4-tolyl)tpy and the aged solution of [Cr(2)(4'-(4-
tolyl)tpy)][CF3SO3]3. 
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Scheme 4. Possible pathways for the reaction of [Cr(2)(4'-(4-tolyl)tpy)]3+ in DMF, DMSO, 
H2O and MeOH. Experimental data for DMF solutions support pathway (ii). 
 
3.4 Electrochemistry 
The electrochemical behaviour of homoleptic and heteroleptic complexes containing 1 and 
4'-(4-tolyl)tpy was investigated by cyclic voltammetry, and the results are given in Table 2. 
Wieghardt and coworkers have proposed [7] that the three reversible reduction processes 
observed for [Cr(tpy)2]3+ are all ligand based, with stepwise reduction occurring 
sequentially on one, then the other, ligand. Each of [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3, 
[Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3 and [Cr(1)2][CF3SO3]3 also exhibits three reversible 
reductions, and in addition, the complexes containing 1 exhibit a reversible oxidation 
(Table 2). The latter is presumably centred on the diphenylamine unit. The first reduction 
step occurs at increasingly more negative potential on going from [Cr(tpy)2]3+ to [Cr(4'-(4-
tolyl)tpy)2]3+ and [Cr(1)(4'-(4-tolyl)tpy)]3+ to [Cr(1)2]3+, and the similarity of the first 
reduction potentials for [Cr(4'-(4-tolyl)tpy)2]3+ and [Cr(1)(4'-(4-tolyl)tpy)]3+ suggests that 
the 4'-(4-tolyl)tpy ligand is the first to be reduced in the heteroleptic complex.  
N
N
N
N
N
N
N
MeO
MeO
= =
Cr3+
Solv
[Cr(Solv)6]3+ + + (i)
Cr3+
Solv
Cr(Solv)3
3+
Cr(Solv)3
3+
(ii)
Cr3+
Solv
Cr3+ Cr3+
+
+ (iii)
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Table 2  Cyclic voltammetric data with respect to Fc/Fc+; MeCN solutions with [nBu4N][PF6] supporting 
electrolyte, and scan rate of 0.1 V s–1. 
Compound Eox1/24+/3+ / V Ered1/23+/2+ / V Ered1/22+/1+ / V Ered1/21+/0 / V 
[Cr(tpy)2][PF6]3 a  –0.533 –0.953 –1.469 
[Cr(4'-(4-tolyl)tpy)2][CF3SO3]3  –0.581 –0.949 –1.278 
[Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3 +0.660 –0.587 –0.955 –1.276 
[Cr(1)2][CF3SO3]3 +0.683 –0.601 –0.955 –1.431 
 a Data from reference [19]. 
 
 
Figure 6. Cyclic voltammogram of [Cr(1)2][CF3SO3]3, measured in MeCN (with respect to 
Fc/Fc+, with [nBu4N][PF6] as supporting electrolyte at a scan rate of 0.1 V s–1). 
 
 
4  Conclusions 
We have prepared and characterized [Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3 and [Cr(2)(4'-(4-
tolyl)tpy)][CF3SO3]3 and the spectroscopic and electrochemical behaviours compared to 
those of [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3 and [Cr(1)2][CF3SO3]3. The single crystal structure 
of [Cr(4'-(4-tolyl)tpy)2][CF3SO3]3.2MeCN reveals packing features which result from the  
need to accommodate three anions and two solvent molecules per cation; embraces 
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between cations differ from those observed with salts of [M(4'-(4-tolyl)tpy)2]2+. The 
characteristic ILCT absorption of 1 or 2 is red-shifted upon coordination to Cr3+ ions, and 
exhibits a negative solvatochromic effect. In CHCl3, CH2Cl2, MeCN, acetone or EtOH, 
[Cr(1)(4'-(4-tolyl)tpy)][CF3SO3]3 and [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 appear to be stable, 
but in H2O, MeOH, DMSO and DMF, the tpy ligands are labile. Changes in the absorption 
spectra of [Cr(2)(4'-(4-tolyl)tpy)][CF3SO3]3 in DMF over time are consistent with the 
formation of [Cr(4'-Xtpy)(DMF)3]3+ rather than complete ligand displacement or a ligand 
redistribution.  
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